medigraphic.com
ISSN 1561-2988 (Print)

2016, Number 1

<< Back Next >>

Rev Cubana Farm 2016; 50 (1)

Pulmonary embolism secondary to inappropriate use of oral contraceptive therapy: a case report

Domínguez-Domínguez CA, Nava-Mesa MO, Calderón-Ospina CA

Language: Spanish
References: 17
Page: 162-170
PDF size: 71.06 Kb.


ABSTRACT

Forty-one year old female admitted to the hospital because of symptoms and signs suggestive of pulmonary thromboembolism which was confirmed by CT angiography. There was no history of prior thromboembolic events, smoking, venous stasis or vascular lesion (negative lupus anticoagulant and anticardiolipins). The only documented hypercoagulability factor was the use of an oral contraceptive containing drospirenone and ethinylestradiol for the last year. The patient was treated with anticoagulants such as enoxaparin and she recovered without sequelae; she is currently under treatment with warfarin as an outpatient. It is known that the use of combined oral contraceptives in patients over 35 years old requires caution, largely due to higher risk of thromboembolic events associated with increased hepatic synthesis of several coagulation factors. Therefore, this case represents a potentially fatal and preventable severe adverse reaction.


REFERENCES

  1. Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC). U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recomm Rep 2013;21:1-60.

  2. American Society of Health System Pharmacists, Inc., DynaMed. Ipswich (MA): EBSCO Information Services. 1995. Record No. 116852, Oral contraceptives; [cited 2014 Nov 14]. Available from: http://web.b.ebscohost.com.ez.urosario.edu.co/dynamed/detail?sid=25fc1d70- eb2d-4c16-8e8f- 7339682903cc%40sessionmgr113&vid=0&hid=116&bdata=JnNpdGU9ZHluYW1lZC1 saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=116852&anchor=top. Last access: september 17th 2015

  3. Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol. 2004;217(1-2):255-61.

  4. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenonecontaining oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344-54.

  5. Seeger JD, Loughlin J, Eng PM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol. 2007;110:587-93.

  6. The Food and Drug Administration. Background Document for Joint Meeting of Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee: NDA 21-098 Yasmin (3 mg drospirenone/0.03 mg ethinyl estradiol), NDA 21-676 YAZ (3 mg drospirenone/0.02 mg ethinyl estradiol), NDA 22-532 Beyaz (3 mg drospirenone/0.02 mg ethinyl estradiol/0.451 mg levomefolate calcium), NDA 22-574 Safyral (3 mg drospirenone/0.03 mg ethinyl estradiol/0.451 mg levomefolate calcium); [cited 2014 Nov 14]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM282462.pdf. Last access: september 17th 2015.

  7. Lidegaard O, Lokkegaard E, Svendsen AL. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890.

  8. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921.

  9. Instituto de Salud Pública, Ministerio de Salud. Gobierno de Chile. Anticonceptivos orales que contienen drospirenona como progestágeno generan un aumento potencial de riesgo de tromboembolismo venoso; [cited 2014 Nov 14]. Available from: http://www.ispch.cl/noticia/19404?page=328. Last access: september 17th 2015

  10. Suchon P, Al Frouh F, Henneuse A. Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILl Genetic Risk Monitoring (PILGRIM) Study. Thromb Haemost 2015;114-16.

  11. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015;350:h2135.

  12. Naranjo CA, Busto U, Sellars EM. A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther. 1981;30:239-45.

  13. The World Health Organization - Uppsala Monitoring Centre. The use of the WHO-UMC system or standardised case causality assessment; [cited 2014 Nov 14]. Available from: http://who-umc.org/Graphics/24734.pdf. Last access: September 17th 2015.

  14. Ouellet-Hellstrom R, Graham DJ, Staffa JA. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints; [cited 2014 Nov 14]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf. Last access: September 17th 2015.

  15. Berresford S. FDA completes drospirenone safety review. Reactions Weekly 2012;1398:2.

  16. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenonecontaining oral contraceptive: final results from the European Active Surveillance 5. Seeger JD, Loughlin J, Eng PM. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. Obstet Gynecol. 2007;110:587-93. 6. The Food and Drug Administration. Background Document for Joint Meeting of Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risk Management Advisory Committee: NDA 21-098 Yasmin (3 mg drospirenone/0.03 mg ethinyl estradiol), NDA 21-676 YAZ (3 mg drospirenone/0.02 mg ethinyl estradiol), NDA 22-532 Beyaz (3 mg drospirenone/0.02 mg ethinyl estradiol/0.451 mg levomefolate calcium), NDA 22-574 Safyral (3 mg drospirenone/0.03 mg ethinyl estradiol/0.451 mg levomefolate calcium); [cited 2014 Nov 14]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM282462.pdf. Last access: september 17th 2015. 7. Lidegaard O, Lokkegaard E, Svendsen AL. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890. 8. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921. 9. Instituto de Salud Pública, Ministerio de Salud. Gobierno de Chile. Anticonceptivos orales que contienen drospirenona como progestágeno generan un aumento potencial de riesgo de tromboembolismo venoso; [cited 2014 Nov 14]. Available from: http://www.ispch.cl/noticia/19404?page=328. Last access: september 17th 2015 10. Suchon P, Al Frouh F, Henneuse A. Risk factors for venous thromboembolism in women under combined oral contraceptive. The PILl Genetic Risk Monitoring (PILGRIM) Study. Thromb Haemost 2015;114-16. 11. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015;350:h2135. 12. Naranjo CA, Busto U, Sellars EM. A method for estimating the probability of adverse drug reactions, Clin Pharmacol Ther. 1981;30:239-45. 13. The World Health Organization - Uppsala Monitoring Centre. The use of the WHO-UMC system or standardised case causality assessment; [cited 2014 Nov 14]. Available from: http://who-umc.org/Graphics/24734.pdf. Last access: September 17th 2015. 14. Ouellet-Hellstrom R, Graham DJ, Staffa JA. Combined Hormonal Contraceptives (CHCs) and the Risk of Cardiovascular Disease Endpoints; [cited 2014 Nov 14]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf. Last access: September 17th 2015. 15. Berresford S. FDA completes drospirenone safety review. Reactions Weekly 2012;1398:2. 16. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenonecontaining oral contraceptive: final results from the European Active Surveillance Revista Cubana de Farmacia. 2016;50(1) http://scielo.sld.cu 170 Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54.

  17. Martínez F, Ramírez I, Pérez-Campos E, Latorre K, Lete I. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Eur J Contracept Reprod Health Care 2012;17:7-29. Adapted from: Apgar BS, Greenberg G. Using Progestins in Clinical Practice. Am Fam Physician. 2000;15:1839-46.




2020     |     www.medigraphic.com